Chinese Tech Stocks in Focus: WuXi Biologics & Kingdee

WuXi Biologics (2269-hk) & Kingdee (268-hk), the two Chinese tech stocks, have shown promising bullish signals...

Uptrend 2

WuXi Biologics ( Consolidate before Next Rally

WuXi Biologics (, a biopharmaceutical group, released a positive profit alert on July 29, stating that 1H net income is expected to increase by more than 58% on year. The company said "more client projects were added into the Group's pipeline expediting the development and manufacturing of potential treatments related to COVID-19 in support of its global clients". 

As shown on the daily chart, WuXi Biologics' share price has finished a measured move after reaching a high at $193.0 on August 6, suggesting a potential consolidation before the next rally. Bullish investors might consider $152.2 as the nearest support, which is the 61.8% Fibonacci retracement of the rally started from March. The 1st and 2nd resistances are expected to be located at $193.0 and $222.0 respectively. Alternatively, a break below $152.2 may open a path to the next support at $139.7.

Source: TradingView, Gain Capital

Kingdee ( Strong Bullish Momentum

Kingdee (, a software company, issued a profit warning in early July, pointing out that it expects to record a 1H net loss of 200 - 300 million yuan compared with a net profit of 110 million yuan last year. However, its share price showed resilience as investor continue to chase technology stocks.

Kingdee's rally, after breaking above a 2-year consolidation range, remains solid. For the stock to keep its strong bullish momentum, the level at $19.70 is expected to act as the nearest support. The 1st and 2nd resistances are expected to be located at $25.30 and $27.00. Alternatively, losing $19.70 might suggest a deeper price correction to $17.00.

Source: TradingView, Gain Capital

Build your confidence risk free

More from Stocks

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.